Acadian Asset Management
PRVB

Acadian Asset Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Acadian Asset Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,956
Closed -$72K – 2062
2019
Q2 		$72K Buy
+5,956
New +$32.4K ﹤0.01% 1424

Other funds holding PRVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Acadian Asset Management's PRVB Position: Q3 2019 in Review

Acadian Asset Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2019, closing a stake of 5,956 shares — an estimated $72K sold.

Acadian Asset Management first reported a position in PRVB in Q2 2019 and held it in 1 quarter. The position peaked at $72K in Q2 2019. 48 funds tracked by Wall St. Rank hold PRVB as of Q3 2019.

  • Acadian Asset Management reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Acadian Asset Management sold 5,956 Provention Bio, Inc. Common Stock shares in Q3 2019, an estimated $72K.
  • Acadian Asset Management first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Acadian Asset Management's Provention Bio, Inc. Common Stock position peaked at $72K in Q2 2019.
  • 48 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2019.

Based on Acadian Asset Management's 13F filing for Q3 2019, filed 7 Nov 2019.